J-LSMS 2017 | Annual Archive

JOURNAL OF THE LOUISIANA STATE MEDICAL SOCIETY

Generic Drug (Trade name)

Adult Dose

Pediatric Dose

FDA Pregnancy Category*

Start Drug

Stop Drug

Potential Adverse Effects

4 weeks

1 week

C

8 mg/kg

500mg q day

Chloroquine phosphate (Aralen®)

• Widespread world resistence • Prolonged QT interval • Torsades de pointes • Blurred vision • Retinopathy • Pruritus • Exacerbated psoriasis

• Nausea and vomiting possible if taken on an empty stomach

Regions with chloroquine-resistant Plasmodium falciparum malaria

7 days

1-2 days

C

Daily dose by weight: • 1/2 ped tab 5-8kg; • 3/4 ped tab 11-20kg; • 2 ped tabs 21-30kg; • 3 ped tabs 31-40kg; • 1 adult tab >40kg.

250/100mg q day

Atovaquone- proguanil (Malarone®)

• Not recommended during pregnancy, during breast- feeding, or for children weighing less than 5kg. Contraindicated with renal impairment (creatinine clearance <30mL/min).

4 weeks

1-2 days

D

Adult dose > 8yrs. of age

100mg q day

Doxycycline hyclate (Vibramycin® et al.)

• Photosensitivity • Esophagitis • Gastritis

• Vaginal yeast infection • Pediatric dental enamel staining ≤ 8 years of age • Only limited resistance in rural areas of Southeast Asia • Vivid dreams • Nightmares • Altered mood • Prolonged QT interval • Av block • Contraindicated in patients with depression, seizure disorder, and psychosis. testing required. • Gastric irritation • Methemoglobinemia • Contraindicated during pregnancy and breast-feeding unless the infant has normal G6PD levels • Failures in P. vivax therapy reported in patients with hepatic CYP2D6 polymorphisms. •Hemolytic anemia with G6PD deficiency; pretherapy

2-3 days 4 weeks

B

Daily dose by weight: 5mg/kg ≤ 9 kg; 1/4 tab 9-19kg; 1/2 tab 20-30kg; 3/4 tab 31-45kg; adult dose > 45kg.

250mg q week

Mefloquine hydrochloride (Lariam®)

1 days

7 days

Avoid in pregnancy

Two 26.3mg tabs (30mg base) q day

Adult dose

Primaquine phosphate- off-label use (generic only). Not recommened in areas with significant P. falciparum risks.

J La State Med Soc VOL 169 SEPTEMBER/OCTOBER 2017 135

Made with FlippingBook Digital Publishing Software